RBC Capital analyst Luca Issi maintained a Buy rating on RegenXBio (RGNX – Research Report) yesterday and set a price target of $35.00. The company’s shares closed yesterday at $16.67.
Issi covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Moderna, and BioMarin Pharmaceutical. According to TipRanks, Issi has an average return of -23.6% and a 20.00% success rate on recommended stocks.
RegenXBio has an analyst consensus of Strong Buy, with a price target consensus of $38.25, implying a 129.45% upside from current levels. In a report released today, Barclays also maintained a Buy rating on the stock with a $55.00 price target.
The company has a one-year high of $28.80 and a one-year low of $11.83. Currently, RegenXBio has an average volume of 671.4K.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RGNX in relation to earlier this year. Most recently, in March 2024, Vittal Vasista, the CFO of RGNX bought 20,041.00 shares for a total of $75,354.16.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
RegenXBio (RGNX) Company Description:
REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
